Brought to you by 
Follow-on nets $54mm for Durata
03 Jun 2021
Executive Summary
Durata Therapeutics Inc. (developing drugs for infectious diseases) netted $54mm through the follow-on public offering of 8.22mm common shares (including the overallotment) at $7 each. The company will use the funds to gain US and EU marketing approval for its lead antibiotic dalbavancin, for its scale-up manufacturing, and to pursue other indications for the compound.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- FOPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Follow-on nets $54mm for Durata
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice